Photys Therapeutics Stock

photys.comHealthcare / BioTech & PharmaFounded: 2022

Photys Therapeutics is a biopharma company that uses its proprietary bifunctional small molecules platform to unlock fine-tuned control of protein function, repair signaling to amplify endogenous disease-fighting mechanisms. Photys was founded by the Broad Institute's leading bifunctional chemist, Amit Choudhary, and the Longwood Fund, alongside a scientific advisory board comprised of distinguished scientists and drug developers.

Register To Buy and Sell Shares

For more details on financing and valuation for Photys Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Photys Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Photys Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Photys Therapeutics investors also invested in these private companies


Management Team

Brian Fenton
President & Chief Executive Officer
Edward Holson, PhD
Chief Science Officer & Co-Founder
Jeff Capello
Interim Chief Financial Officer

Board Members

Lizzie Ngo
Longwood Fund
David Steinberg
Luke Evnin
MPM Capital
Otello Stampacchia
Omega Funds
Briggs Morrison
Syndax Pharmaceuticals
Alon Lazarus
Investment Partner

Frequently Asked Questions About Photys Therapeutics’ Stock

Can you buy Photys Therapeutics’ stock?
Photys Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Photys Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Photys Therapeutics’ stock?
Yes, you can sell stock of a private company like Photys Therapeutics. Forge can help you sell your Photys Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Photys Therapeutics’ stock price?
Photys Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Photys Therapeutics’ private market stock price with Forge Data.
What is Photys Therapeutics’ stock ticker symbol?
Photys Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Photys Therapeutics raises $75M in Series A funds to control disease-causing proteins
Photys Therapeutics has debuted with a $75 million Series A funding round. The startup focuses on phosphorylation-inducing chimeric small molecules (PHICS) — a new class of bifunctional medicines that can direct and repair protein phosphorylation.
Updated on: Apr 15, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.